Teva Pharmaceutical Industries (TEVA 1.18%) received some bad news last week after its oral multiple sclerosis drug laquinimod received a negative opinion by the EU's CHMP. In this video, Motley Fool health-care analyst Max Macaluso takes a look at what this decision means for Teva today, and where the company needs to strategically go from here following this decision.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Can Teva Rebound After This Rejection?
By Max Macaluso
–
Jan 31, 2014 at 6:45PM
NYSE: TEVA
Teva Pharmaceutical Industries
Market Cap
$19B
Today's Change
(1.18%) $0.20
Current Price
$16.75
Price as of June 27, 2025, 3:58 p.m. ET
Teva got some very bad news last week. Will the company be able to bounce back?
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Teva Pharmaceutical Industries. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Teva Pharmaceutical Industries
TEVA
$16.75
(1.18%)
$0.20
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Why Teva Pharmaceuticals Stock Blasted 6% Higher Today
Why Teva Pharmaceutical Stock Is Soaring Today
Why Teva Pharmaceutical Stock Is Sinking Today
Teva Pharmaceutical Industries (TEVA) Q4 2024 Earnings Call Transcript
My Top 10 Portfolio Holdings for 2025
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.